Only small 503A pharmacies are covered. One Florida compounder plans to make just one of the six peptides, and Public Citizen says Kennedy undermined the FDA.
Recap by typeshit. Full story at NPR.
Per @pamelajeannoble, the letter flags contamination risks, manufacturing conditions and compounded copies resembling approved drugs.
Gounder notes the policy requires no testing of finished vials or deadline for side effect reports, and public comments on the draft run through November 13.
Healio
Durrani tells Healio the move bypassed rulemaking and FDA scientists, and warns patients may wrongly read it as FDA approval while long-term data is missing.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
2:08
A local TV segment looks at why Lilly's experimental retatrutide is getting so much coverage next to Ozempic.
For some people on GLP-1 drugs, losing weight opens up clothing options they didn't have before, and with them new ways to express identity.
Loading…